Loading clinical trials...

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis | Clinical Trials | Clareo Health

TERMINATEDPHASE4

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular PalmoPlantar and Genital Psoriasis (Psoriatyk Special Sites)

NCT06042920•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and women diagnosed with stable plaque psoriasis with involvement of the palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
•Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
•Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a 5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.
•* A total maximum of 5 sterile pustules across both palms and soles limited only to psoriatic plaques will be allowed.
•Evidence of typical plaque psoriasis outside palms and soles at both screening visit and Day 1.
•Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
•Failed to respond to, or intolerant of ≥ 1 topical therapy.
•Men and women diagnosed with stable plaque psoriasis with involvement of the genital area for at least 6 months or more. Stable psoriasis is defined as no morphology changes or significant flares of disease activity in the opinion of the investigator.
•Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale at both screening visit and Day 1.
•Moderate-to-severe GenPs, defined as static Physician's Global Assessment of Genitalia (s-PGA-G) score of ≥ 3 on a 6-point scale at both screening visit and Day 1.
+3 more criteria

Exclusion Criteria

•Target Disease Exceptions
•Has non-plaque psoriasis (for PP pustulosis, PP pustular psoriasis, isolated pustules on palms or soles with or without erythema outside psoriatic plaques, guttate, pustular, erythrodermic, and drug-induced psoriasis) at screening or Day 1.

Locations (31)

Local Institution - 0050

Phoenix, Arizona, United States

Local Institution - 0015

Fountain Valley, California, United States

Local Institution - 0009

Los Angeles, California, United States

Local Institution - 0004

Santa Monica, California, United States

Local Institution - 0057

Skokie, Illinois, United States

Local Institution - 0052

Indianapolis, Indiana, United States

Local Institution - 0053

Plainfield, Indiana, United States

Local Institution - 0029

Rockville, Maryland, United States

Local Institution - 0012

Detroit, Michigan, United States

Local Institution - 0005

East Windsor, New Jersey, United States

Key Dates

Start Date

October 9, 2023

Primary Completion Date

April 25, 2025

Completion Date

April 25, 2025

Last Updated

July 15, 2025

Enrollment

130

ACTUAL participants

Conditions

Palmoplantar PsoriasisGenital Psoriasis

Interventions

Deucravacitinib

DRUG

Placebo

DRUG

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

NCT06029257

Genital Psoriasis

View study

COMPLETEDPHASE4

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

NCT05969223

Genital PsoriasisScalp Psoriasis

View study

UNKNOWN

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)

Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Brodalumab in Palmoplantar Psoriasis